SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

Multiple Myeloma Clinical Trial Solutions

MAKING STRIDES TOWARD NEW TREATMENTS ONE STUDY AT A TIME

The third most common blood cancer, multiple myeloma (MM) is a complex, dynamic disease. Survival rates have improved recently because of treatments that offer a chance at durable remission, but high-risk MM remains an area of urgent and unmet need. Signant Health applies decades of clinical oncology experience and clinical trial technology solutions in our SmartSignals™ suite to help study teams deliver new therapies and treatments sooner.

OPTIMIZE PROM RELIABILITY & EXPEDITE STUDY START-UP

Key endpoints in MM trials require reliable patient-reported outcome measurement (PROM) data. Signant's pre-configured eCOA solution for oncology provides electronic, pre-validated oncology instruments that help patients provide complete, accurate, and timely responses, improving PRO accuracy compared to paper and pencil.

In addition, launching studies faster can help expand the reach and impact of potential therapies and treatments. Signant's pre-configured eCOA solution enables **33% faster study start-up at 20% less cost.**

PREVENT WASTE AND REDUCE SHIPMENTS & RETURNS

MM studies often involve multiple patient cohorts and complex dosing schedules. Another variable adding complexity, investigational products for these and other oncology studies can be expensive as well as limited in supply and shelf life.

Signant's RTSM system utilizes unique algorithms to implement complex randomization schemes rapidly and optimize lot usage and efficiency. We support your study with a project team of multidisciplinary clinical science and operations experts from launch to closeout.

INCREASE PATIENT COMPREHENSION AND EASE BURDENS FOR SITES & PATIENTS

Patient-reported outcome measures (PROMs) are vital to fully evaluate MM treatment risk-benefit profiles. Our eCOA solution can be tailored to your protocol and patient population's needs – guided assessments and built-in edit checks reduce errors while alerts and reminders improve adherence to medication dosing schedules.

COLLECT MORE COMPLETE PATIENT FUNCTION DATA

Help your study team collect accurate data about treatment effects on patient function. We integrate ActiGraph with our eCOA system to automatically collect sleep and activity data without imposing additional burdens on patients or sites. Study teams can view this data alongside COA data for a more complete evaluation of patient function.

DIGITIZE STUDIES FOR END-TO-END ACCURACY & VISIBILITY

While all of our solutions can be used as standalone tools, when combined they enhance the accuracy and efficiency of your multiple myeloma study. Gain immediate access to electronic data for faster decision-making and improved regulatory inspections.

Signant's end-to-end suite of evidence generation solutions and accompanying multiple myeloma clinical science and medicine expertise reduce burdens for participants and study teams while generating more accurate, reliable data.

SIGNANT'S MULTIPLE MYELOMA CLINICAL TRIAL SOLUTIONS EXPERIENCE

Phases

I II III IV

82 Languages

6,400 Sites

57 Countries

16,000 Patients

90 Trials

COMMON INSTRUMENTS USED

EORTC-QLQ-MY20 | FACT-MM | EORTC-QLQ-MT20
HM-PRO | EORTC-QLQ-C30

SMARTSIGNALS SOLUTIONS

The solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

Pre-configured eCOA

RTSM

Sensors & wearables

eConsent

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics

MEET THE EXPERTS